The FDA is stepping up oversight of fledgling medical treatments that aim to harness the potential of stem cells—as well as some businesses the agency said were selling unapproved and possibly harmful treatments.
from WSJ.com: US Business http://ift.tt/2wjrdTX
via IFTTT
No comments:
Post a Comment